Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.34 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.30 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.30 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306627 | 0.91 | MAOB (0.33) | SMYD2NR1H4 | |
| SCHEMBL2218007 | 0.84 | MRGPRX4 (0.32) | MRGPRX4HMGB1CXCL12HTTCYP3A4 | |
| SCHEMBL2357120 | 0.82 | — | — | |
| SCHEMBL1564661 | 0.81 | HTT (0.44) | MRGPRX4HTT | |
| SCHEMBL2306631 | 0.80 | CYP3A4 (0.30) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL3062273 | 0.80 | KDM4E (0.36) | SMN1; SMN2SMYD2 | |
| SCHEMBL5014338 | 0.80 | KDM4E (0.36) | SMN1; SMN2SMYD2 | |
| SCHEMBL34474697 | 0.78 | MAPT (0.44) | MRGPRX4HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL3253890 | 0.76 | IDO1 (0.35) | — | |
| SCHEMBL2309995 | 0.76 | RIPK1 (0.33) | HTTCYP3A4SMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | MRGPRX4 616/4885HMGB1 3228/4885CXCL12 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.